Taysha Gene Therapies (TSHA) Share-based Compensation (2020 - 2026)

Taysha Gene Therapies has disclosed Share-based Compensation across 7 years of filings, most recently posting $5.5 million for Q1 2026.

• Share-based Compensation for Q1 2026 came in at $5.5 million, up 68.4% year-over-year; the trailing twelve-month figure through Mar 2026 was $15.6 million (up 17.82% YoY), and the FY2025 annual result was $13.3 million, up 1.49% from the prior year.
• Share-based Compensation came in at $5.5 million for Q1 2026 at Taysha Gene Therapies, up from $3.5 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $5.5 million in Q1 2026 to a low of $1.7 million in Q1 2023.
• The 5-year median for Share-based Compensation is $3.3 million (2025), against an average of $3.4 million.
• Across the five-year window, Share-based Compensation plunged 68.57% in 2023 and jumped 90.93% in 2024, its largest moves.
• Taysha Gene Therapies' Share-based Compensation stood at $4.1 million in 2022, then sank by 52.04% to $2.0 million in 2023, then soared by 63.41% to $3.2 million in 2024, then increased by 9.73% to $3.5 million in 2025, then soared by 57.18% to $5.5 million in 2026.
• The last three Share-based Compensation figures came in at $5.5 million (Q1 2026), $3.5 million (Q4 2025), and $3.3 million (Q3 2025), per Business Quant data.